Neurospecific proteins in cerebrospinal fluid and in the bloodserum of patients with amyotrophic lateral sclerosis

Rushkevich Yu.N.

Republican Research and Clinical Center of Neurology and Neurosurgery, Minsk, Belarus

Pashkovskaia I.D.

Respublikanskiĭ nauchno-prakticheskiĭ tsentr nevrologii i neĭrokhirurgii Ministerstva zdravookhraneniia Respubliki Belarus', Minsk

Likhachev S.A.

Respublikanskiĭ nauchno-prakticheskiĭ tsentr nevrologii i neĭrokhirurgii Ministerstva zdravookhraneniia Respubliki Belarus', Minsk

Neurospecific proteins in cerebrospinal fluid and in the bloodserum of patients with amyotrophic lateral sclerosis

Authors:

Rushkevich Yu.N., Pashkovskaia I.D., Likhachev S.A.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(5): 75‑80

DOI: 10.17116/jnevro20181185175

Downloaded: 30

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Rushkevich YuN, Pashkovskaia ID, Likhachev SA. Neurospecific proteins in cerebrospinal fluid and in the bloodserum of patients with amyotrophic lateral sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(5):75‑80. (In Russ.)
https://doi.org/10.17116/jnevro20181185175

Close metadata

Objective. To determine concentrations of neurospecific enolase (NSE) and S100b protein in bloodserum and cerebrospinal fluid (CSF) in patients with amyotrophic lateral sclerosis (ALS) with different forms (onset) and duration of ALS. Material and methods. Concentrations of NSE and S100b in serum and CSF were studied in 86 patients with different forms and duration of ALS. Results and conclusion. Concentrations of NSE and S100b protein in CSF were significantly higher in the group of patients with bulbar form and in the group with duration of disease less than 1 year compared to the control group. There was a negative correlation of S100b protein in CSF with ALSFRSR score in the group of patients with bulbar ALS. An increase in NSE concentration in CSF and serum in patients with cervico-thoracic form of ALS and in patients with disease duration from 1 to 4 years was found. Concentrations of protein S100b remained the same. A significant decrease in the concentration gradient of S100b protein (CSF/serum) in patients with disease duration more than 1 year suggests the disturbances of blood-brain barrier permeability with increasing ALS duration and confirms the role of these changes in the pathogenesis of the disease.

Keywords:

amyotrophic lateral sclerosis

neurospecific enolase

S100b

serum

cerebrospinal fluid

Authors:

Rushkevich Yu.N.

Republican Research and Clinical Center of Neurology and Neurosurgery, Minsk, Belarus

Pashkovskaia I.D.

Respublikanskiĭ nauchno-prakticheskiĭ tsentr nevrologii i neĭrokhirurgii Ministerstva zdravookhraneniia Respubliki Belarus', Minsk

Likhachev S.A.

Respublikanskiĭ nauchno-prakticheskiĭ tsentr nevrologii i neĭrokhirurgii Ministerstva zdravookhraneniia Respubliki Belarus', Minsk

List of references:

Reynolds A, Laurie C, Mosley RL, Gendelman HE. Oxidative stress and the pathogenesis of neurodegenerative disorders. International Review of Neurobiology. 2007;82:297-325. https://doi.org/10.1016/s0074-7742(07)82016-2
Brilev LV, Zaharova MN, Zavalishin IA, Gulyaeva NV. Narushenie gemato-entsefalicheskogo bar’era pri bokovom amiotroficheskom skleroze: sovremennie aspekti. Neirohimiya. 2012;1:75-82. (In Russ.)
Skvortsova VI, Limborskaya SA, Slominskii PA, Brusov OS, Karahan VB, Gerasimova MM, Levitskaya NI, Levitskii GN, SHadrina MI, Kondrat’eva EA, Alehin AV, Serdyuk AV, Botvinenko TМ. Assotsiatsiya po gomozigotnosti po korotkomu allelyu (S) tyazhelih neirofilamentov s bolezn’yu dvigatel’nogo neirona i razvitiem oksidantnogo stressa. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2003;103:2:38-44. (In Russ.)
Migheli A, Cordera S, Bendotti C, Atzori C, Piva R, Schiffer D. S-100β protein is upregulated in astrocytes and motor neurons in the spinal cord of patients with amyotrophic lateral sclerosis. Neuroscience Letters. 1999;261:25-28. https://doi.org/10.1016/s0304-3940(98)01001-5
Steiner J, Bogerts B, Schroeter ML, Bernstein H-G. S100B protein in neurodegenerative disorders. Clinical Chemistry and Laboratory Medicine. 2011;49(3). Accessed 2011-02-09. Available at: https://doi.org/10.1515/CCLM.2011.083
Casmiro M, Maitan S, De Pasquale F, Cova V, Scarpa E, Vignatelli L. Cerebrospinal fluid and serum neuron-specific enolase concentrations in a normal population. Eur J Neurol. 2005;12(5):369-374. https://doi.org/10.1111/j.1468-1331.2004.01021.x
Bettermann K, Slocomb JE. Clinical relevance of biomarkers for traumatic brain injury. In: Biomarkers for Traumatic Brain Injury. Eds. Dambinova S., Hayes R.L., Wang K.K.W. Cambridge: Royal Society of Chemistry; 2012. https://doi.org/10.1039/9781849734745-00001
Anand N, Stead LG. Neuron-specific enolase as a marker for acute ischemic stroke: a systematic review. Cerebrovasc Dis. 2005;20(4):213-219. https://doi.org/10.1159/000087701
Zukova NG, Gashilova FF. Neiron-spetsificheskaya enolaza v sivorotke krovi kak diagnosticheskii marker parkinsonizma. Byulleten’ sibirskoi meditsini. 2005;3:28-33. (In Russ.)
Donato R. S100: a multigenic family of calcium-modulated proteins of EF-hand type with intracellular and extracellular functional roles. Int J Biochem Cell Biol. 2001;33(7):637-668. https://doi.org/10.1016/s1357-2725(01)00046-2
Blyth BJ, Farhavar A, Gee C, Hawthorn B, He H, Nayak A, Stöcklein V, Bazarian JJ. Validation of serum markers for blood-brain barrier disruption in traumatic brain injury. J Neurotrauma. 2009;26(9):1497-1507. https://doi.org/10.1089/neu.2008.0738
Norris F, Shepherd R, Denys E, Kwei U, Mukai E, Elias L, Holden D, Norris H. Onset, natural history and outcome in idiopathic adult motor neuron disease. Journal of the Neurological Sciences. 1993;118(1):48-55. https://doi.org/10.1016/0022-510x(93)90245-t
Brooks BR, Miller RG, Swash M, et al. World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1(5):293-299. https://doi.org/10.1080/146608200300079536
Revised criteria for the diagnosis of amyotrophic lateral sclerosis. Accessed November 8, 2005. http://www.wfnals.org/guidelines/1998elescorial/elescorial1998.htm
Okita T, Nodera H, Shibuta Y, Nodera A, Asanuma K, Shimatani Y, Sato K, Izumi Y, KajiCan R. Awaji ALS criteria provide earlier diagnosis than the revised El Escorial criteria? J Neurol Sci. 2011;302(1-2):29-32. https://doi.org/10.1016/j.jns.2010.12.007
Cedarbaum J, Stambler N. Performance of the Amyotrophic Lateral Sclerosis Functional Rating Scale(ALSFRS) in multicenter clinical trials. Journal of the Neurological Sciences. 1997;152(1):1-9. https://doi.org/10.1016/s0022-510x(97)00237-2
Kaufmann P, Levy G, Thompson JL, Delbene ML, Battista V, Gordon PH, Rowland LP, Levin B, Mitsumoto H. The ALSFRSr predicts survival time in an ALS clinic population. Neurology. 2005;64(1):38-43. https://doi.org/10.1212/01.WNL.0000148648.38313.64
Steinacker P, Huss A, Mayer B, Grehl T, Grosskreutz J, Borck G, Kuhle J, Lulé D, Meyer T, Oeckl P, Petri S, Weishaupt J, Ludolph AC, Otto M. Diagnostic and prognostic significance of neurofilament light chain NF-L, but not progranulin and S100B, in the course of amyotrophic lateral sclerosis: Data from the German MND-net. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(1-2):112-119. https://doi.org/10.1080/21678421.2016.1241279
Migheli A, Cordera S, Bendotti C, Atzori C, Piva R, Schiffer D. S-100β protein is upregulated in astrocytes and motor neurons in the spinal cord of patients with amyotrophic lateral sclerosis. Neurosci Lett. 1999;261(1-2):25-28. https://doi.org/10.1016/s0304-3940(98)01001-5
Otto M, Bahn E, Wiltfang J, Boekhoff I, Beuche W. Decrease of S100 beta protein in serum of patients with amyotrophic lateral sclerosis. Neurosci Lett. 1998;240(3):171-173. https://doi.org/10.1016/s0304-3940(97)00947-6
Süssmuth SD, Sperfeld AD, Hinz A, Brettschneider J, Endruhn S, Ludolph AC, Tumani H. CSF glial markers correlate with survival in amyotrophic lateral sclerosis. Neurology. 2010;74(12):982-987. https://doi.org/10.1212/WNL.0b013e3181d5dc3b
Yаhno NN, Chehonin VP, Preobrazhenskaya IS. Pronitsaemost’ gematoentsefalicheskogo bar’era pri bolezni Al’tsgeimera i Parkinsonizme s kognitivnimi narusheniyami. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2001;101(5):39-42. (In Russ.)

Close metadata